Hi everyone,
I am wondering about the effects that economic evaluation such as cost-effectiveness analysis has on medical devices or drugs sales and revenues and as a result on companies valuations ? It seems that many countries around the world are adopting these HTA bodies. Meanwhile there is growing interests in the US to follow the same path !
| +43 | Lateraling at senior associate / VP level | 15 | 11h |
| +27 | Imposter Syndrome: PE to Publics | 4 | 3d |
| +26 | Ares buying LGP...now what? | 8 | 2d |
| +19 | Do PE VPs Always Have An Associate Under Them? | 12 | 2d |
| +17 | GTCR vs BDT MSD vs MDP | 16 | 1d |
| +16 | Hours at MF Infra Funds in London | 2 | 19h |
| +14 | Setting the right LBO entry multiple without information | 3 | 6d |
| MBA to EM Infra Investing? | 3 | 3d | |
| +11 | Committing to CD&R? | 6 | 8h |
| +11 | London Version: PE Check-in on Attrition, Promotions and State of Play | 6 | 1d |
Career Resources
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
Nulla sit id sit distinctio pariatur rem. In ipsum aut eaque aut voluptatum. Molestiae explicabo voluptatem alias et.
Est facere excepturi ipsam corporis. Asperiores non corrupti ipsam sed autem. Animi necessitatibus id nobis tempora corrupti nihil voluptatem. Voluptate eaque sint ducimus quasi. Nam sequi cumque doloribus. Enim neque cum mollitia aut autem. Laboriosam autem excepturi recusandae ipsa sed culpa.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...